Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small molecule platform...
-
Inflammasome inhibitors in combination with GLP-1 agonists have potential to address unmet medical needs of people living with obesity.
-
UMeWorld study shows DAGola oil lowers uric acid, triglycerides, cholesterol, and weight - supporting metabolic health with up to 50% fewer triglycerides.
-
UMeWorld Achieves Major Milestone with U.S. Pilot Bottling of DAGola Functional Oils; Announces New High-Performance Chef Blend
-
Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity modelObese state completely reversed with 30% weight loss and...
-
Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
-
Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
-
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Pha
-
Northstrive Biosciences Announces Positive FDA Pre-IND Response Supporting IND Submission of EL-22 to Conduct Phase 2 Clinical Trial for Obesity Treatment
-
Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new...